Skip to main content

Table 4 Classification of ADR (n = 246)

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

ADR according to SOC Incidence of ADR Time to onset
Acute (within 60 min) Subacute (1 to 24 h) Latent (after 2 days)
Blood and lymphatic system disorders
     Anaemia 2 (0.8%) 0 1 1
Cardiac disorders
     QT prolongation 34 (13.8%) 0 9 25
     Bradycardia 4 (1.6%) 0 1 3
     ST elevation 1 (0.4%) 0 0 1
     Palpitation 1 (0.4%) 0 0 1
Gastrointestinal disorders
     Diarrhoea 76 (30.9%) 0 49 27
     Nausea and vomiting 27 (11.0%) 1 7 19
     Abdominal pain 4 (1.6%) 0 2 2
Hepatobiliary disorders
     Hyperbilirubinaemia (without jaundice) 77 (31.3%) 0 17 60
     Elevated liver transaminases 6 (2.4%) 0 0 6
     Hyperbilirubinaemia (with jaundice) 5 (2.0%) 0 3 2
     Elevated alkaline phosphatase 1 (0.4%) 0 0 1
Nervous system disorders
     Giddiness 3 (1.2%) 1 0 2
     Headache 1 (0.4%) 0 1 0
Renal and urinary disorders
     Acute kidney injury 2 (0.8%) 0 1 1
Skin and subcutaneous tissue disorders
     Rash 2 (0.8%) 0 1 1
  1. Incidence of ADR is reported as n (%), where % is calculated by number of ADR/n